Application of cyclic dinucleotide (cGAMP) in anti-tumor field

Patent metadata

Field	Value
Publication number	US-10092592-B2
Application number	US-201515304924-A
Country	US
Kind code	B2
Filing date	Apr 20, 2015
Priority date	Apr 21, 2014
Publication date	Oct 9, 2018
Grant date	Oct 9, 2018

Abstract

The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs.

First claim

What is claimed is:

1. A method for treating a malignant tumor in a subject in need thereof comprising administering to the subject a composition consisting essentially of cGAMP.

2. The method of claim 1 , wherein the malignant tumor is a gastric tumor.

3. The method of claim 1 , wherein the malignant tumor is a lung tumor.

4. The method of claim 1 , wherein the malignant tumor is a colon tumor.

5. The method of claim 1 , wherein the malignant tumor is a liver tumor.

6. The method of claim 1 , wherein the malignant tumor is a prostate tumor.

7. The method of claim 1 , wherein the malignant tumor is a pancreatic tumor.

8. The method of claim 1 , wherein the administering is performed systemically.

9. The method of claim 1 , wherein the composition is administered daily for 2 weeks or more.

10. The method of claim 1 , wherein the treatment results in reduced tumor weight relative to untreated controls.

11. A method for inhibiting tumor growth comprising contacting tumor cells with a composition consisting essentially of cGAMP.

12. The method of claim 11 , wherein the tumor cells are selected from the group consisting of gastric carcinoma cells, lung adenocarcinoma cells, colorectal carcinoma cells, hepatocellular carcinoma cells, prostatic carcinoma cells, and pancreatic carcinoma cells.

13. The method of claim 11 , wherein the tumor cells are from human gastric carcinoma cell line MNK-45.

14. The method of claim 11 , wherein the tumor cells are from human lung adenocarcinoma cell line A549.

15. The method of claim 11 , wherein the tumor cells are from human colorectal carcinoma cell line Lovo.

16. The method of claim 11 , wherein the tumor cells are from hepatocellular carcinoma cell line SMMC-7721.

17. The method of claim 11 , wherein the tumor cells are from prostatic carcinoma cell line PC-3.

18. The method of claim 11 , wherein the tumor cells are from pancreatic carcinoma cell line SW1990.

19. A method for treating a malignant tumor in a subject in need thereof comprising administering to the subject a composition consisting essentially of an anti-tumor drug and a pharmaceutically acceptable carrier, wherein the anti-tumor drug comprises cGAMP, and the malignant tumor is a hepatocellular carcinoma or a gastric carcinoma.

Assignees

• Univ Fudan

Inventors

• Tan Xiangshi
• Li Tiejun
• Xu Qiming
• Pan Jie
• Rui Yaocheng
• Cheng Hao
• Zhang Yuefan

Classifications

• A61K31/708

  having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/706

  containing six-membered rings with nitrogen as a ring hetero atom · CPC title

• A61K31/7076

  containing purines, e.g. adenosine, adenylic acid · CPC title

• A61K31/7084 Primary

  Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide · CPC title